Does Tirzepatide Cause Cancer? Reviewing the Current Evidence

If you just searched “does tirzepatide cause cancer,” chances are you are a little worried right now. That is completely understandable. You saw a warning on the label, or someone mentioned it, and now you want a straight answer before you continue treatment or before you even start.

So here it is: no, current human evidence does not show that tirzepatide causes cancer. There is an FDA warning on the label that patients deserve to understand, and there are specific medical histories that make tirzepatide off-limits entirely. But for most people, the science available today is more reassuring than the label might suggest at first glance.

This article explains exactly what triggered that warning, what dozens of large human studies have actually found, and what questions are still being answered. By the end, you will have everything you need to have an informed, confident conversation with your provider.

What Is the FDA Boxed Warning and Why Does It Exist?

A boxed warning is the FDA’s most serious safety alert. It appears on the drug label to make sure both doctors and patients are fully aware of a significant risk before using a medication.

For tirzepatide, this warning exists because of studies conducted in rats. According to the official FDA prescribing information for Mounjaro® and Zepbound®, tirzepatide caused thyroid C-cell tumors in rats in a two-year study at clinically relevant doses. The FDA was transparent about this finding and required the boxed warning across the entire GLP-1 drug class as a precaution.

Two important things to know about those rat studies. First, rats have a much higher density of GLP-1 receptors on their thyroid C-cells than humans do. This biological difference is one reason researchers believe the rodent findings may not translate directly to human risk. Second, the studies used doses administered twice weekly, whereas humans take tirzepatide once weekly. The FDA acknowledged these differences but maintained the warning as a precautionary measure.

A separate 6-month study in transgenic mice showed no tumor formation, and tirzepatide was not found to be genotoxic in a bone marrow assay. Still, the FDA took the cautious path and required the warning. That is the right call when there is an animal signal, and it is not something to dismiss.

The FDA has also required Eli Lilly to conduct a 15-year registry study to monitor MTC rates in the US population and detect any increase that might be linked to tirzepatide use. That kind of long-term monitoring is exactly what responsible post-market surveillance looks like.

What Human Studies Actually Show

Here is the reassuring part: the human data, across tens of thousands of patients, has not shown a cancer signal.

The SURPASS clinical trial program tested tirzepatide across five major trials, plus the cardiovascular outcomes trial SURPASS-CVOT, which enrolled 13,299 patients across 640 sites in 30 countries and followed them for a median of four years. No thyroid cancer signals attributable to tirzepatide emerged across any of these studies.

A 2025 systematic review and meta-analysis published in Endocrinology and Metabolism pulled together all available randomized controlled trials of tirzepatide and assessed cancer risk across 16 different cancer types. The conclusion: no statistically significant increase in risk was found for any of them, including thyroid, pancreatic, breast, colon, lung, prostate, ovarian, and renal cancers.

A 2025 retrospective cohort study using the TriNetX database of millions of patients compared thyroid cancer rates in tirzepatide users versus matched controls. After careful statistical adjustment, tirzepatide users actually showed a lower incidence of malignant thyroid cancer (Relative Risk 0.348; p less than 0.001). The researchers concluded the findings fail to support the association suggested by the boxed warning.

A separate meta-analysis published in Diabetes Research and Clinical Practice (2024) also found no increase in cancer incidence among tirzepatide users across all specific cancer types evaluated.

It is worth saying plainly: the evidence so far is genuinely reassuring for people without the contraindicated conditions. That does not mean the question is fully closed, since tirzepatide is still relatively new and long-term data takes time to accumulate. But the data we do have is pointing in a good direction.

What a Decade of GLP-1 Data Tells Us

Tirzepatide has been available since 2022, so it is still a newer medication. But it belongs to a class of drugs that has been used in millions of people for more than a decade, and that broader safety record is relevant.

In November 2025, a major analysis published in Diabetes, Obesity and Metabolism reviewed data from 93 clinical trials of liraglutide and semaglutide, post-marketing surveillance from a large safety database, and real-world insurance claims data. The conclusion across all three data sources: no association between GLP-1 receptor agonist use and thyroid cancer was found.

In January 2025, the American Thyroid Association highlighted a landmark international cohort study analyzing data from 92,497 GLP-1 users and over 2.4 million comparison patients across six countries. No evidence of increased thyroid cancer risk was found.

A Mayo Clinic commentary on that same study described the growing body of evidence as reinforcing confidence in the absence of a clinically significant causal relationship between GLP-1 receptor agonists and thyroid cancer.

The European Medicines Agency reviewed the full body of GLP-1 observational and surveillance data in October 2023 and reached the same conclusion: no evidence of a causal relationship between GLP-1 receptor agonists and thyroid cancer. No changes to product labeling were required.

One important biological note: researchers have measured calcitonin levels (a marker of thyroid C-cell activity) in human patients on GLP-1 drugs over multiple years. No consistent calcitonin elevation has been found in humans, which is meaningfully different from what is seen in rats. This biological gap further weakens the case for direct translation of the rodent findings to human patients.

A Closer Look at Thyroid Cancer

Medullary Thyroid Carcinoma (MTC)

MTC is a rare subtype that accounts for roughly 3 to 4 percent of all thyroid cancers. It arises from the same type of C-cells studied in the rat experiments. This is the cancer specifically referenced in the boxed warning.

People with a personal or family history of MTC, or with MEN 2 syndrome, should not use tirzepatide. This is an absolute contraindication and is not negotiable.

If you are taking tirzepatide and experience a lump in your neck, persistent hoarseness, difficulty swallowing, or difficulty breathing, contact your provider right away. These are potential symptoms of thyroid tumors. The FDA prescribing information notes that routine calcitonin testing or thyroid ultrasounds are not recommended for most tirzepatide users without MTC risk factors, as they can lead to unnecessary procedures. A calcitonin level above 50 ng/L warrants further evaluation.

Other Types of Thyroid Cancer

For thyroid cancers beyond MTC, the picture is also reassuring. A July 2025 retrospective cohort study published in Diabetes Care, analyzing data from six population-based healthcare databases, found no evidence that GLP-1 receptor agonist use was associated with increased thyroid tumor risk.

Some earlier observational studies found a possible elevated risk, but subsequent analyses with larger and more rigorous methodology have largely attributed those findings to detection bias. 

Patients taking GLP-1 drugs tend to have more medical appointments and more imaging, which means more incidental findings that are not necessarily caused by the medication. Obesity itself also raises thyroid cancer risk, making it difficult to separate the medication’s effect from the underlying condition being treated.

A Closer Look at Pancreatic Cancer

Early concerns about pancreatic cancer emerged because GLP-1 drugs affect pancreatic cells. The data on this is now quite reassuring.

A 2025 meta-analysis published in Endocrinology, Diabetes and Metabolism reviewed 62 randomized controlled trials involving 66,232 patients and found no statistically significant association between GLP-1 receptor agonist use and pancreatic cancer.

A January 2026 study using the TriNetX database of over 150 million patients went even further, finding that GLP-1 receptor agonist use was associated with a significantly lower 5-year incidence of pancreatic cancer in patients with chronic pancreatitis, a group already at elevated baseline risk (HR 0.49; 95% CI 0.30 to 0.80). This is an observational finding and should be interpreted carefully, but it adds to the reassuring picture.

Who Should Not Use Tirzepatide

These contraindications are firm. Tirzepatide should not be used by:

• People with a personal history of medullary thyroid carcinoma (MTC)
• People with a family history of medullary thyroid carcinoma (MTC)
• People with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• People with a known serious hypersensitivity to tirzepatide

Discuss tirzepatide with your provider before starting if you have thyroid nodules, a history of pancreatitis, or a strong family history of endocrine cancers.

What Ongoing Surveillance Looks Like

The FDA has required Eli Lilly to run a 15-year registry study specifically tracking MTC rates in the United States, with the goal of detecting any increase that might be linked to tirzepatide. This was explicitly noted in a 2025 FDA warning letter to Eli Lilly, which also reminded the company that the boxed warning must not be minimized or omitted in any promotional communications.

The FDA’s Adverse Event Reporting System and the Sentinel Initiative also continuously monitor real-world safety data. Through 2024, no unexpected cancer patterns had emerged that required new label changes beyond the existing thyroid C-cell tumor warning.

The science is evolving, and that is expected for a newer medication. What matters is that the surveillance infrastructure is in place and actively monitoring.

The Bottom Line

Taking a step back: the available evidence, taken together, is more reassuring than alarming for most patients. Here is what the science shows:

• The FDA boxed warning exists and should be taken seriously. It is based on animal data, not confirmed human cases.
• People with a personal or family history of MTC, or with MEN 2, should not use tirzepatide. This is absolute.
• Multiple large human studies, international cohort analyses, and post-marketing surveillance data have not found a causal link between tirzepatide and cancer.
• The class of drugs tirzepatide belongs to has been used safely in millions of people for over a decade without establishing a human cancer connection.
• Long-term data continues to accumulate, and a dedicated 15-year registry study is actively tracking any emerging signal.

For patients who do not have the contraindicated conditions, the current evidence does not support avoiding tirzepatide because of cancer concerns. That said, your individual history matters, and your provider is the right person to help you weigh your personal risk and benefits.

This article is for informational and educational purposes only. It does not constitute medical advice. No patient cancer history is discussed herein. Always consult your healthcare provider before starting, stopping, or changing any medication.